Jenoptik (JEN) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
12 Nov, 2025Executive summary
Revenue and EBITDA declined year-over-year, but order intake surged in Q3, supporting future growth potential.
Free cash flow improved significantly, and cost-saving and restructuring programs were implemented.
The group reorganized into four Strategic Business Units to enhance customer focus and efficiency.
Focus areas for growth include AI-driven semiconductors, optical communications, defense, and AR/VR applications.
Restructuring costs (high single-digit million EUR) are included in 2025 guidance, with most impact in Q4.
Financial highlights
Revenue for the first nine months was €753.2 million, down 7.6% year-over-year; EBITDA fell 17.9% to €131.8 million.
Gross margin decreased to 31.9% from 33.9%; EBITDA margin at 17.5% (down 220 bps year-over-year).
Earnings per share at €0.80 versus €1.15 last year; earnings after tax were €47.0 million, down 29.7%.
Free cash flow rose 35.7% to €84.6 million; net debt reduced to €366.3 million, leverage at 1.9x.
Capital expenditure fell 19.8% to €58.3 million.
Outlook and guidance
2025 revenue and EBITDA margin expected at the lower end of guidance, reflecting persistent market uncertainty.
Cost-saving measures and further FTE reductions planned to offset inflationary pressures.
Capital expenditure for 2025 anticipated to be significantly below prior year.
Management expects growth in 2026, assuming stable macroeconomic and political conditions.
Midterm strategic update planned for next year.
Latest events from Jenoptik
- Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025